Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Multiple sclerosis therapies differentially affect SARS-CoV-2 vaccine–induced antibody and T cell immunity and function
Joseph J. Sabatino, Kristen Mittl, William Rowles, et al.
JCI Insight (2022) Vol. 7, Iss. 4
Open Access | Times Cited: 75

Showing 1-25 of 75 citing articles:

A common allele of HLA is associated with asymptomatic SARS-CoV-2 infection
Danillo G. Augusto, Lawton D. Murdolo, Demetra S.M. Chatzileontiadou, et al.
Nature (2023) Vol. 620, Iss. 7972, pp. 128-136
Open Access | Times Cited: 140
T Cell Responses to SARS-CoV-2
Alessandro Sette, John Sidney, Shane Crotty
Annual Review of Immunology (2023) Vol. 41, Iss. 1, pp. 343-373
Closed Access | Times Cited: 114
Vaccination and immunotherapies in neuroimmunological diseases
Alexander Winkelmann, Micha Loebermann, Michael Barnett, et al.
Nature Reviews Neurology (2022) Vol. 18, Iss. 5, pp. 289-306
Open Access | Times Cited: 42
Targets and cross-reactivity of human T cell recognition of common cold coronaviruses
Alison Tarke, Yun Zhang, Nils Methot, et al.
Cell Reports Medicine (2023) Vol. 4, Iss. 6, pp. 101088-101088
Open Access | Times Cited: 25
Molecular mimicry in multisystem inflammatory syndrome in children
Aaron Bodansky, Robert C. Mettelman, Joseph J. Sabatino, et al.
Nature (2024) Vol. 632, Iss. 8025, pp. 622-629
Open Access | Times Cited: 12
High frequencies of alpha common cold coronavirus/SARS-CoV-2 cross-reactive functional CD4+ and CD8+ memory T cells are associated with protection from symptomatic and fatal SARS-CoV-2 infections in unvaccinated COVID-19 patients
Pierre-Grégoire Coulon, Swayam Prakash, Nisha R. Dhanushkodi, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 8
S1PR1 inhibition induces proapoptotic signaling in T cells and limits humoral responses within lymph nodes
Dhaval Dixit, Victoria M. Hallisey, Ethan Y.S. Zhu, et al.
Journal of Clinical Investigation (2024) Vol. 134, Iss. 4
Open Access | Times Cited: 7
Persistently reduced humoral and sustained cellular immune response from first to third SARS-CoV-2 mRNA vaccination in anti-CD20-treated multiple sclerosis patients
Hamza Mahmood Bajwa, Frederik Novak, Anna Christine Nilsson, et al.
Multiple Sclerosis and Related Disorders (2022) Vol. 60, pp. 103729-103729
Open Access | Times Cited: 28
A quest for universal anti-SARS-CoV-2 T cell assay: systematic review, meta-analysis, and experimental validation
Akshay Binayke, Aymaan Zaheer, Siddhesh Vishwakarma, et al.
npj Vaccines (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 6
Role of antiviral CD8+ T cell immunity to SARS-CoV-2 infection and vaccination
Vivien Karl, Maike Hofmann, Robert Thimme
Journal of Virology (2025)
Open Access
Immune responses to SARS‐CoV‐2 vaccination in multiple sclerosis: a systematic review/meta‐analysis
Grace Gombolay, Monideep Dutt, William R. Tyor
Annals of Clinical and Translational Neurology (2022) Vol. 9, Iss. 8, pp. 1321-1331
Open Access | Times Cited: 26
Cellular and Humoral Immunity to SARS‐CoV‐2 Infection in Multiple Sclerosis Patients on Ocrelizumab and Other Disease‐Modifying Therapies: A Multi‐Ethnic Observational Study
Ilya Kister, Y. Patskovsky, Ryan Curtin, et al.
Annals of Neurology (2022) Vol. 91, Iss. 6, pp. 782-795
Open Access | Times Cited: 24
Humoral and Cellular Response to Spike of Delta SARS-CoV-2 Variant in Vaccinated Patients With Multiple Sclerosis
Linda Petrone, Carla Tortorella, Alessandra Aiello, et al.
Frontiers in Neurology (2022) Vol. 13
Open Access | Times Cited: 24
Longitudinal characterisation of B and T-cell immune responses after the booster dose of COVID-19 mRNA-vaccine in people with multiple sclerosis using different disease-modifying therapies
Alessandra Aiello, Andrea Coppola, Serena Ruggieri, et al.
Journal of Neurology Neurosurgery & Psychiatry (2022) Vol. 94, Iss. 4, pp. 290-299
Open Access | Times Cited: 22
Inducing broad-based immunity against viruses with pandemic potential
Alessandro Sette, Erica Ollmann Saphire
Immunity (2022) Vol. 55, Iss. 5, pp. 738-748
Open Access | Times Cited: 21
Is humoral and cellular response to SARS-CoV-2 vaccine modified by DMT in patients with multiple sclerosis and other autoimmune diseases?
Ana Zabalza, Georgina Arrambide, Susana Otero‐Romero, et al.
Multiple Sclerosis Journal (2022) Vol. 28, Iss. 7, pp. 1138-1145
Closed Access | Times Cited: 20
Humoral and cellular immunity in convalescent and vaccinated COVID-19 people with multiple sclerosis: Effects of disease modifying therapies
Mario Habek, Željko Cvetić, Ana Savić Mlakar, et al.
Multiple Sclerosis and Related Disorders (2022) Vol. 59, pp. 103682-103682
Open Access | Times Cited: 19
Preserved T cell responses to SARS-CoV-2 in anti-CD20 treated multiple sclerosis
Tatjana Schwarz, Carolin Otto, Terry C. Jones, et al.
Multiple Sclerosis Journal (2022) Vol. 28, Iss. 7, pp. 1041-1050
Open Access | Times Cited: 18
B‐cell repopulation dynamics and drug pharmacokinetics impact SARS‐CoV‐2 vaccine efficacy in anti‐CD20‐treated multiple sclerosis patients
Klara Asplund Högelin, Nicolas Ruffin, Elisa Pin, et al.
European Journal of Neurology (2022) Vol. 29, Iss. 11, pp. 3317-3328
Open Access | Times Cited: 18
Dynamic Evolution of Humoral and T-Cell Specific Immune Response to COVID-19 mRNA Vaccine in Patients with Multiple Sclerosis Followed until the Booster Dose
Serena Ruggieri, Alessandra Aiello, Carla Tortorella, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 10, pp. 8525-8525
Open Access | Times Cited: 10
A Broad-Spectrum Multi-Antigen mRNA/LNP-Based Pan-Coronavirus Vaccine Induced Potent Cross-Protective Immunity Against Infection and Disease Caused by Highly Pathogenic and Heavily Spike-Mutated SARS-CoV-2 Variants of Concern in the Syrian Hamster Model
Swayam Prakash, Nisha R. Dhanushkodi, Mahmoud Singer, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 3
Clinical usefulness of testing for severe acute respiratory syndrome coronavirus 2 antibodies
Harry Alexopoulos, Ioannis P. Trougakos, Meletios Α. Dimopoulos, et al.
European Journal of Internal Medicine (2022) Vol. 107, pp. 7-16
Open Access | Times Cited: 15
Longitudinal adaptive immune responses following sequential SARS-CoV-2 vaccinations in MS patients on anti-CD20 therapies and sphingosine-1-phosphate receptor modulators
Joseph J. Sabatino, Kristen Mittl, William Rowles, et al.
Multiple Sclerosis and Related Disorders (2022) Vol. 70, pp. 104484-104484
Open Access | Times Cited: 14
COVID-19 Vaccine Response in People with Multiple Sclerosis Treated with Dimethyl Fumarate, Diroximel Fumarate, Natalizumab, Ocrelizumab, or Interferon Beta Therapy
Aliya Jaber, Meera H. Patel, Andrew Sylvester, et al.
Neurology and Therapy (2023) Vol. 12, Iss. 2, pp. 687-700
Open Access | Times Cited: 8
Low protection from breakthrough SARS-CoV-2 infection and mild disease course in ocrelizumab-treated patients with multiple sclerosis after three mRNA vaccine doses
Frederik Novak, Hamza Mahmood Bajwa, John Coia, et al.
Journal of Neurology Neurosurgery & Psychiatry (2023) Vol. 94, Iss. 11, pp. 934-937
Open Access | Times Cited: 8
Page 1 - Next Page

Scroll to top